• Connect
  • Bookmark Us
  • AF Twitter
  • AF YouTube
  • AF LinkedIn
  • Subscribe
  • Subscription Link
Arent Fox
  • Firm

    • History

    • Awards & Recognitions

    • Diversity

      • Overview
      • Diversity Scholarship
      • Employees on Diversity
      • LGBT Initiative
      • Women’s Leadership Development Initiative
    • Alumni

    • Pro Bono

      • Overview
      • Current Pro Bono Work
      • Community Involvement
      • Pro Bono Newsletter
      • Pro Bono Awards & Honors
      • FAQ: Pro Bono & Working at Arent Fox
    • Leadership

      • Firm Management
      • Administrative Leadership
  • Deals & Cases

  • People

  • Practices & Industries

    • Practices

      • Advertising, Promotions & Data Security
      • Government Relations
      • Antitrust & Competition Law
      • Health Care
      • Appellate
      • Insurance & Reinsurance
      • Bankruptcy & Financial Restructuring
      • Intellectual Property
      • Commercial Litigation
      • International Trade
      • Communications, Technology & Mobile
      • Labor & Employment
      • Construction
      • Municipal & Project Finance
      • Consumer Product Safety
      • OSHA
      • Corporate & Securities
      • Political Law
      • ERISA
      • Real Estate
      • Environmental
      • Tax
      • FDA Practice (Food & Drug)
      • Wealth Planning & Management
      • Finance
      • White Collar & Investigations
      • Government Contractor Services
    • Industries

      • Automotive
      • Energy Law & Policy
      • Fashion, Luxury Goods & Retail
      • Government Real Estate & Public Buildings
      • Hospitality
      • Life Sciences
      • Long Term Care & Senior Living
      • Media & Entertainment
      • Medical Devices
      • Nonprofit
      • Sports
  • Newsroom

    • Alerts

    • Events

    • Media Mentions

    • Press Releases

    • Social Media

    • Subscribe

  • Careers

    • Lawyers

    • Law Students

    • Professional Staff

  • Contact

    • Washington, DC

    • New York, NY

    • Los Angeles, CA

    Alerts

    • Newsroom Overview
      • Alerts

        Alerts by Criteria

        E.g., 1 / 21 / 2013
        E.g., 1 / 21 / 2013
      • Events
      • Media Mentions
      • Press Releases
      • Social Media
      • Subscribe

    You are here

    Home » Newsroom » Alerts

    Share

    • Printer-friendly version
    • Send by email
    • A Title
    • A Title
    • A Title
    • A
    • A
    • A

    FDA Issues Final Order Restricting Use of Antibiotic for Veterinary Use

    January 13, 2012

    On January 6, 2012, the Food and Drug Administration published a Final Order (as a Final Rule) in the Federal Register prohibiting using the antibiotic cephalosporin for “disease prevention” in food-producing animals, particularly cattle, swine, chickens and turkeys. Cephalosporin helps prevent disease on ranches and farms where crowded animal conditions are prevalent. FDA’s Order is intended to prohibit the “prophylactic use” of cephalosporin in the major species of food-producing animals. While Cephalosporin will still be allowed to treat illness in animals (as this is not viewed as a prophylactic use), FDA’s order will have to a substantial impact on the agricultural community. Cephalosporin is commonly used in humans to treat pneumonia, skin/soft tissue infections, pelvic inflammatory disease, diabetic foot infections, and urinary tract infections. FDA believes that bacterial resistance to cephalosporin has the potential to impact public health as the antibiotic (e.g., Keflex and generic Cephalexin) is regularly used to treat pneumonia and salmonella infections. Testing conducted by the Centers for Disease Control in 2009 found roughly 3 percent of salmonella tested was cephalosporin-resistant. While many in industry have charged that FDA needs a stronger scientific basis in order to justify imposing use restrictions on ranchers and farmers, US Rep. Louise M. Slaughter, D-NY, (among others) believes FDA should broaden the Order.

    We expect this issue to remain contentious for both government and the farm/agricultural industry for the foreseeable future. Significantly, FDA is accepting public comments on the Order through March 6, 2012. The new restrictions are set to become effective on April 5, 2012. Interested parties who may be adversely impacted by the Order may submit comments to FDA and provide recommendations to make the Order less onerous to the agriculture community.

    To view the Final Order, please click here.

    Related People

    • James H. Hartten*
    • Georgia Ravitz
    • James R. Ravitz

    Related Practices

    FDA Practice (Food & Drug)
    • Firm
    • Deals & Cases
    • People
    • Practices & Industries
    • Newsroom
    • Careers
    • Contact

    Footer Main

    • Firm
    • Deals & Cases
    • People
    • Practices & Industries
    • Newsroom
    • Careers
    • Subscribe
    • Alumni
    • Diversity
    • Legal Notice
    • Privacy Policy
    • Social Media Disclaimer
    • Nondiscrimination
    • Site Map
    • Client/Staff Login

    Offices

    • Washington, DC
      1717 K Street, NW
      Washington, DC 20036
      Tel: 202.857.6000
    • New York, NY
      1675 Broadway
      New York, New York 10019
      Tel: 212.484.3900
    • Los Angeles, CA
      555 West Fifth Street, 48th Floor
      Los Angeles, California 90013
      Tel: 213.629.7400
    • © Copyright 2013 Arent Fox LLP. All Rights Reserved.

      Legal Disclaimer
      Contents may contain attorney advertising under the laws of some states. Prior results do not guarantee a similar outcome.